Federman & Sherwood Announces an Investigation into Sesen Bio

Rhea-AI Summary

Federman & Sherwood has initiated an investigation into Sesen Bio (NASDAQ: SESN) for potential violations of federal securities laws during the Class Period from August 9, 2021, to August 13, 2021. The complaint alleges that the company made material false representations that artificially inflated the stock price. The lawsuit aims to recover damages for investors who purchased shares during this period and allows potential lead plaintiffs to step forward by October 15, 2021.

Positive

• None.

Negative

• Allegations of issuing false misrepresentations could undermine investor confidence.
• Potential legal expenses and liabilities may affect the company's financial health.

Federman & Sherwood announces an investigation into Sesen Bio (NASDAQ: SESN). The complaint will allege violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 9, 2021 through August 13, 2021.

To learn how to participate in this action, please visit
https://www.federmanlaw.com/blog/federman-sherwood-announces-an-investigation-into-sesen-bio-for-potential-securities-law-violations/

The lawsuit seeks to recover damages on behalf of all Sesen Bio investors who purchased common stock during the Class Period. You may move the Court no later than October 15, 2021 to serve as a lead plaintiff for the entire Class.

If you wish to discuss this action, obtain further information and participate in this litigation, or should you have any questions regarding this notice or preservation of your rights, please contact: Priscilla Scoggins at pms@federmanlaw.com or visit the firm’s website at www.federmanlaw.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005889/en/

FAQ

What is the investigation about Sesen Bio (SESN)?

The investigation by Federman & Sherwood concerns potential violations of federal securities laws, specifically related to false misrepresentations made from August 9 to August 13, 2021.

What are the potential consequences of the Sesen Bio investigation?

If the allegations are proven true, Sesen Bio may face financial liabilities, legal expenses, and a decline in investor confidence.

How can investors participate in the Sesen Bio lawsuit?

Investors who purchased Sesen Bio shares during the Class Period may move the court by October 15, 2021, to serve as a lead plaintiff.